Share on StockTwits

Investment analysts at Citigroup Inc. dropped their price target on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from $97.00 to $86.00 in a note issued to investors on Monday. Citigroup Inc.’s price objective would indicate a potential downside of 10.55% from the stock’s previous close.

A number of other firms have also recently commented on GWPH. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Friday, May 16th. They now have a $103.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of GW Pharmaceuticals PLC- from $79.00 to $90.00 in a research note on Thursday, May 8th. They now have an “outperform” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of GW Pharmaceuticals PLC- from $65.00 to $102.00 in a research note on Thursday, May 8th. They now have a “buy” rating on the stock. Six analysts have rated the stock with a buy rating, GW Pharmaceuticals PLC- has an average rating of “Buy” and an average target price of $90.75.

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up 6.68% on Monday, hitting $102.56. The stock had a trading volume of 1,381,173 shares. GW Pharmaceuticals PLC- has a 52 week low of $8.50 and a 52 week high of $97.64. The stock has a 50-day moving average of $75.90 and a 200-day moving average of $61.02. The company’s market cap is $1.791 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.44. The company had revenue of $12.55 million for the quarter, compared to the consensus estimate of $12.48 million. The company’s revenue for the quarter was up 63.6% on a year-over-year basis. Analysts expect that GW Pharmaceuticals PLC- will post $-2.07 EPS for the current fiscal year.

GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.